tirzepatide banned by fda Announces End To Compounded March 19, 2025 US judge sides with FDA's

The drug seems to cause even more weight loss than semaglutide, Yanovski says

Understanding Strive Pharmacy accreditation and quality When you inject medication into your body weekly, the quality and reliability of that medication matters enormously

Head-to-Head Superiority (SURMOUNT-5): The SURMOUNT-5 trial, with detailed results published in The New England Journal of Medicine on May 11, 2025, directly compared Tirzepatide (Zepbound) with semaglutide (Wegovy)

Unrealistic Expectations and Individual Variation The issue: Weight loss results vary from person to person due to genetics, metabolic differences, and lifestyle factors

Genetic Testing and Personalized Risk Assessment with PlexusDx The PlexusDx Precision Peptide Genetic Test analyzes GIPR (rs1800437), FTO (rs9939609), and MC4R (rs17782313) variants that relate to GLP-1 and related signaling pathways